SuperworthGilead Sciences EPS GILD
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- −$2.67
- Latest quarter, Q2 FY26
- −$8.45
- −642% on a year earlier
- Fiscal year 2025
- $6.77
- +1730% on the year before
Gilead Sciences' earnings per share was −$2.67 over the twelve months to Jun 30, 2026, down 153% on a year earlier.
In its latest quarter, Q2 FY26, it was −$8.45, down 642% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $6.77 | +1730% |
| FY2024 | $0.37 | −92% |
| FY2023 | $4.50 | +23% |
| FY2022 | $3.65 | −26% |
| FY2021 | $4.93 | +6063% |
| FY2020 | $0.08 | −98% |
| FY2019 | $4.21 | +1% |
| FY2018 | $4.16 | +20% |
| FY2017 | $3.48 | −65% |
| FY2016 | $9.94 | −17% |
| FY2015 | $11.92 | +62% |
| FY2014 | $7.38 | +303% |
| FY2013 | $1.83 | +12% |
| FY2012 | $1.64 | −8% |
| FY2011 | $1.77 | +8% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$8.45 | −642% | −$2.67 | |
| Q1 FY26 | $1.61 | +55% | $7.34 | |
| Q4 FY25 | $1.74 | +23% | $6.77 | |
| Q3 FY25 | $2.43 | +143% | $6.45 | |
| Q2 FY25 | $1.56 | +21% | $5.02 | |
| Q1 FY25 | $1.04 | n/a | $4.75 | |
| Q4 FY24 | $1.42 | +25% | $0.37 | |
| Q3 FY24 | $1.00 | −42% | $0.09 | |
| Q2 FY24 | $1.29 | +55% | $0.82 | |
| Q1 FY24 | −$3.34 | −518% | $0.36 | |
| Q4 FY23 | $1.14 | −12% | $4.50 | |
| Q3 FY23 | $1.73 | +22% | $4.66 |
Against its peers
Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GILDGilead Sciences | −$2.67 | −153% a year |
| PFEPfizer | $0.76 | −60% a year |
| AMGNAmgen | $16.09 | +32% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| MRKMerck | $1.25 | −81% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| BIIBBiogen | $5.65 | −46% a year |
| LLYEli Lilly and | $29.80 | +95% a year |
| Peer median | $5.09 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Gilead Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.